IRD
Opus Genetics, Inc.
5.00$
-1.9%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | -107.8% | – | – | |
| – | +166.7% | -50.0% | +0.0% | +50.0% | +66.7% | +430.0% | |
| – | +389.0% | +27.1% | -5.6% | +94.2% | -4.2% | +1.1% | |
| – | +221.0% | -84.2% | -3,169.1% | – | -24.2% | -169.7% | |
| – | -100.0% | – | – | – | – | – | |
| – | – | -118.6% | – | – | – | – | |
| – | – | – | – | – | – | +92.4% | |
| – | – | – | -200.0% | -100.0% | – | – | |
| – | +349.0% | +30.7% | -86.3% | +137.2% | -53.4% | +1,095.0% | |
| – | +1,268.5% | -45.3% | +122.5% | -56.5% | -356.5% | – | |
| – | – | – | – | -107.8% | – | – |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.